Menlo Park, Calif. and Dallas, Texas – January 10, 2022 – ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary selective organ targeting (SORT) LNP delivery platform, today announced that Company leadership will present virtually at the 40th Annual J.P. Morgan Healthcare Conference.

  • Presentation details:
    Date: Thursday, January 13, 2022
    Time: 9:00 a.m. – 9:25 a.m. ET
    Presenter: David Lockhart, Ph.D., President & Chief Scientific Officer

The presentation will be accessible to registered conference attendees.

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit and follow us on Twitter @ReCodeTx and LinkedIn.

Media Contact:
Will Zasadny
Canale Communications, Inc.
[email protected]
(619) 961-8848

Investor Contact:
Sarah McCabe
Stern Investor Relations
[email protected]
[email protected]